Rainer Strohmenger - Profile and Investment Details

Investor Profile

Rainer Strohmenger is a Venture Capital, Private Equity Firm, Finance Operator based in Munich, Bavaria, Germany with a diverse investment portfolio that includes companies such as Aignostics, ImmobilienScout24, invendo medical GmbH, WaveLight: An Alcon Company, Definiens, The Tissue Phenomics Company, invendo medical, NEUWAY Pharma GmbH, GMD Gesellschaft für medizinische Datenverarbeitung mbH, eGenesis, Inc., Actelion, iOmx Therapeutics AG, Adrenomed AG, AMBOSS, Roche mtm laboratories AG, HepaRegeniX GmbH, 20/10 Perfect Vision AGUroMems, MTM Laboratories, Oxford Immunotec, Definiens, Quanta, 4SC AG, Advanced Medical Balloons, Quanta Dialysis Technologies, Neuway Pharma, SphingoTec, Implanet, Koa Health, NoemaLife, Technolas Perfect Vision, Grandis Biotech, Immobilien Scout, Immatics Biotechnologies, Genticel, . Over time, Rainer Strohmenger has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Rainer Strohmenger is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Digital Therapeutics, Regenerative Medicine, Genetics, Autonomous Vehicles, Wellness, Women Founded, Enterprise Software, Immunotherapy, Fundraising, Investment Management, Digital Media, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Banking, Information Technology (IT), Venture Fundraising, Mobile, Technology, Finance, Software, Biotechnology, Medical Devices, Genomics, Precision Medicine, Innovation, Clinical Trials, FinTech, Natural Language Processing, Consumer Internet, Consumer Software, Gene Therapy, Early Stage IT, EarlyStage Technology, Health Diagnostics, Digital Health, Medical, SaaS, Information Technology, B2B, Therapeutics, Cellular Therapy, Pharmaceuticals may find it worthwhile to explore potential connections with Rainer Strohmenger, as their portfolio suggests a familiarity and interest in this area.

Understanding Rainer Strohmenger’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.